Protara officer covers taxes with 3,724 shares

Protara Therapeutics reported an insider share withholding by its Chief Scientific Operations Officer, Jacqueline Zummo.

Rhea-AI Filing Summary

Protara Therapeutics reported an insider share withholding by its Chief Scientific Operations Officer, Jacqueline Zummo. On January 26, 2026, 3,724 shares of common stock were withheld at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award that was granted on January 24, 2025. After this tax-related transaction, Zummo beneficially owns 118,559 shares of Protara common stock directly.

Insider Trade Summary

Exercise Price or Tax Liability: 3,724 shares

Exercise Price or Tax Liability 1 txn

Insider Zummo Jacqueline

Role Chf Scientific Operations Off

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,724	$6.67	$25K

Holdings After Transaction: Common Stock — 118,559 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Protara Therapeutics (TARA) disclose?

Protara disclosed that Chief Scientific Operations Officer Jacqueline Zummo had 3,724 shares of common stock withheld on January 26, 2026 to cover taxes on a vesting restricted stock unit award.

What does the 3,724-share transaction in Protara (TARA) stock represent?

The 3,724 shares represent stock withheld by Protara to satisfy income tax obligations arising from the vesting of a restricted stock unit award granted to Jacqueline Zummo on January 24, 2025.

How many Protara (TARA) shares does Jacqueline Zummo own after this Form 4?

Following the reported tax withholding, Jacqueline Zummo beneficially owns 118,559 shares of Protara Therapeutics common stock in direct ownership.

What is transaction code "F" in the Protara (TARA) Form 4 filing?

In this Form 4, transaction code "F" indicates shares were withheld by the issuer to pay taxes due upon the vesting of an equity award, rather than an open-market buy or sell.

Was this Protara (TARA) insider transaction an open-market sale?

No. The filing states the shares were withheld by the issuer to satisfy tax obligations on a vesting restricted stock unit award, not sold in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zummo Jacqueline

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chf Scientific Operations Off

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		F		3,724(1)	D	$6.67	118,559	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025.

Remarks:

	/s/ Jacqueline Zummo	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.